Hope S. Rugo, MD, from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses pathway changes in breast cancer.
Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses pathway changes in breast cancer.
There are a number of trials looking at mutations in the PI3K pathways to determine whiter patients have a mutation in those pathways are more likely to benefit from PI3K inhibitors. The real need, Rugo says, is in exploring pathway changes: mutations in multiple parts of the same pathway. Trials in this space include neoadjuvant studies as well as adjuvant studies that have a longer time to endpoint.
Rugo says that the I-SPY trial embodies this concept: A novel agent is compared with standard treatment and serial biopsies allow researchers to analyze general pathways changes to identify which tumors will benefit from a specific treatment. This method could direct the oncology community to smaller trials in the future that are directed to the right tumor biology.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More